Heart attack

February 11, 2018

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing  Pyridoxamine and Omeprazole   increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/February/2018, 12.09 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
February 11, 2018

Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Lansoprazole (LP)  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 11/February/2018, 11.56 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of […]
February 2, 2018

Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Rosuvastatin, Docosahexaenoic acid and 5 aminolevulinic acid  decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 3/February/2018, 12.29 am

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]
February 2, 2018

Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and  Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 3/February/2018, 12.20 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and  Hydralazine suppresses tumor suppressor INK4a/p16 expression, […]